The mechanism of the action of dipeptidyl peptidase-4 inhibitors and its use in type 2 diabetes
10.3760/cma.j.issn.1000-6699.2011.11.025
- VernacularTitle:DPP-4抑制剂的作用机制及在2型糖尿病治疗中的应用
- Author:
Dalong ZHU
;
Ping LI
- Publication Type:Journal Article
- Keywords:
Dipeptidyl peptidase-4 inhibitors;
Incretin;
Glucagon-like peptide-1;
Diabetes mellitus,type 2
- From:
Chinese Journal of Endocrinology and Metabolism
2011;27(11):后插5-后插8
- CountryChina
- Language:Chinese
-
Abstract:
The critical role of α- and β-cell dysfunction in the development of type 2 diabetes has been established.Dipeptidyl peptidase-4 (DPP-4) inhibitors are new class of oral anti-hyperglycemia agents that acts to increase active levels of the incretin hormone glucagon-like peptide-1 ( GLP-1 ) and glucose-dependent insulinotropic polypeptide ( GIP),which improved α- and β-cell function.This action is shown as improved α- and β-cell sensitivity to glucose,increased glucose-dependent insulin secretion and decreased glucagon secretion.DPP-4 inhibitors treatment has also been associated with beneficial extrapancreatic effects,including improved peripheral insulin sensitivity and lipid metabolism.Additionally,DPP-4 inhibitors have shown a minimal risk of hypoglycemia and bodyweight neutrality without effects on gastric emptying.Numerous clinical trials have verified the favorable efficacy,safety,and tolerability of DPP-4 inhibitors treatment in monotherapy or combination with other anti-diabetic agents for patients with type 2 diabetes.
